Adaptimmune Extends Funding Runway Ahead Of Clinical Results In Second Half
UK T-cell receptor biotech, Adaptimmune, has raised $100m from a direct offering of its ADSs as it prepares for the reporting of clinical response data later this year from early clinical studies in cancer patients.
You may also be interested in...
Two years after its first big Navacim-based tie-up with Novartis, Parvus could earn beyond $800m in autoimmune R&D pact with Genentech. Iconic licenses ADC tech from Zymeworks, then out-licenses lead candidate to Exelixis.
Biopharma investor sentiment plunged at the end 2018, but soared as the J.P. Morgan Healthcare Conference kicked off with another big company acquisition and as industry participants indicated their optimism about financing and deal-making opportunities in 2019.
Building manufacturing capacity, educating physicians, and reaching agreements with pricing and reimbursement bodies are just some of the hurdles CAR-T therapies have to jump over in Europe, following their approval by the EU Commission earlier this week.